Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KSHN001034
- Development stage
- Phase 1
- Lead developer
- Kashiv BioSciences
- Modality
- Small Molecules
- Administration
- Intramuscular, Subcutaneous
01
Overview
KSHN001034 is a **small molecule drug** under development as an **intramuscular or subcutaneous prodrug of fulvestrant**, designed to act as an **estrogen receptor antagonist** (specifically, a selective estrogen receptor degrader, or SERD). Its mechanism of action mirrors fulvestrant, binding to and promoting degradation of the estrogen receptor, thereby blocking estrogen signaling. KSHN001034 is being evaluated for its safety, tolerability, and pharmacokinetic equivalence to Faslodex (fulvestrant) in healthy postmenopausal women, with the goal of offering a potentially improved or alternative formulation for hormone receptor-positive breast cancer therapy[1][3][7][8][10].
- Other names
- fulvestrant biosimilarKashiv fulvestrant
02
Targets
ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on KSHN001034.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KSHN001034.